PRISM BioLab and Elix Collaborate on AI-Driven Drug Discovery

PRISM BioLab and Elix have announced a strategic collaboration to accelerate drug discovery for protein-protein interaction (PPI) targets, announced in a press release. This partnership, effective from April 1, 2025, aims to combine PRISM BioLab's peptide mimetic technology with Elix's AI drug discovery platform to create a novel drug discovery pipeline.

The collaboration seeks to address the challenges of generating clinical candidate molecules, which traditionally require synthesizing numerous compounds. By integrating PRISM BioLab's PepMetics® technology with Elix's AI platform, the partnership aims to efficiently identify promising compounds for difficult targets, thereby accelerating the creation of breakthrough drug candidates. This approach is expected to reduce time and costs while improving the success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs.